Autres langues Fennec Pharmaceuticals Inc. Toronto S.E.

Actions

FRX

CA31447P1009

Produits pharmaceutiques

Marché Fermé - Toronto S.E. 16:11:44 28/09/2026			Varia. 5j.	Varia. 1 janv.
15,43 ^CAD	+2,59%		+2,87%	+45,57%

17/09	Fennec Pharmaceuticals annonce une présentation orale des résultats détaillés de l’étude clinique de phase 2 STS-J01 initiée par des investigateurs sur Pedmark au Japon au SIOP 2026	CI
12/08	Fennec Pharmaceuticals Inc. : B. Riley reste à l'achat	ZM

Autres langues

17/09	Fennec Pharmaceuticals Announces Oral Presentation Of Detailed Results From Investigator-Initiated Phase 2 STS-J01 Clinical Study Of Pedmark In Japan At SIOP 2026
17/09	Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026
11/08	Fennec Pharmaceuticals at Multi-Year High After Swing to Q2 Earnings Beat
11/08	Fennec Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
11/08	Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
05/08	Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026
29/06	Fennec Pharmaceuticals Inc.(NasdaqCM:FENC) dropped from Russell 2000 Value Benchmark
29/06	Fennec Pharmaceuticals Inc.(NasdaqCM:FENC) dropped from Russell Microcap Value Benchmark Index
29/06	Fennec Pharmaceuticals Inc.(NasdaqCM:FENC) dropped from Russell 3000E Value Benchmark
29/06	Fennec Pharmaceuticals Inc.(NasdaqCM:FENC) dropped from Russell 3000 Value Benchmark
29/06	Fennec Pharmaceuticals Inc.(NasdaqCM:FENC) dropped from Russell Small Cap Comp Value Benchmark
29/06	Fennec Pharmaceuticals Inc.(NasdaqCM:FENC) dropped from Russell 2500 Value Benchmark
22/06	Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
16/06	Fennec Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
15/06	Fennec Pharmaceuticals : Announces Results of Annual Meeting
15/06	Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
10/06	Fennec Announces Results of Annual Meeting
22/05	Fennec Announces New Research Supporting Pedmark's Use at ASCO Annual Meeting
22/05	Fennec Pharmaceuticals Announced New Research Supporting Integration and Use of PEDMARK at 2026 ASCO Annual Meeting
22/05	Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of Pedmark
22/05	Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
18/05	Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18/05	Fennec Pharmaceuticals : Corporate Presentation May 2026
14/05	Fennec Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
14/05	Fennec Pharmaceuticals up 12.6% in U.S. Pre-Market on Q1 Earnings as Pedmark Sales Jump 73%